# A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine

> **NCT06615375** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **LimmaTech Biologics AG** · enrollment: 120 (estimated)

## Conditions studied

- Shigellosis

## Interventions

- **BIOLOGICAL:** Shigella4V2
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06615375
- **Lead sponsor:** LimmaTech Biologics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-12
- **Primary completion:** 2026-04
- **Final completion:** 2026-09
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06615375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06615375, "A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06615375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*